X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (747) 747
index medicus (590) 590
prasugrel hydrochloride (505) 505
ticlopidine - analogs & derivatives (500) 500
clopidogrel (429) 429
male (408) 408
prasugrel (382) 382
female (369) 369
platelet aggregation inhibitors - therapeutic use (366) 366
middle aged (345) 345
platelet aggregation inhibitors - adverse effects (338) 338
aged (290) 290
thiophenes - therapeutic use (287) 287
piperazines - therapeutic use (286) 286
ticlopidine - therapeutic use (284) 284
treatment outcome (275) 275
percutaneous coronary intervention (270) 270
cardiac & cardiovascular systems (265) 265
piperazines - adverse effects (241) 241
thiophenes - adverse effects (241) 241
ticlopidine - adverse effects (240) 240
platelet aggregation inhibitors - administration & dosage (239) 239
adenosine - analogs & derivatives (230) 230
acute coronary syndromes (216) 216
acute coronary syndrome - drug therapy (211) 211
hemorrhage - chemically induced (185) 185
ticlopidine - administration & dosage (182) 182
ticagrelor (175) 175
piperazines - administration & dosage (174) 174
thiophenes - administration & dosage (174) 174
aspirin (170) 170
purinergic p2y receptor antagonists - therapeutic use (152) 152
adenosine - therapeutic use (149) 149
risk factors (149) 149
purinergic p2y receptor antagonists - adverse effects (136) 136
pharmacology & pharmacy (127) 127
platelet aggregation - drug effects (126) 126
prasugrel hydrochloride - therapeutic use (126) 126
abridged index medicus (124) 124
drug therapy, combination (124) 124
time factors (122) 122
acute coronary syndrome (120) 120
prasugrel hydrochloride - adverse effects (119) 119
platelet aggregation inhibitors - pharmacology (118) 118
blood platelets - drug effects (116) 116
coronary heart disease (116) 116
prasugrel hydrochloride - administration & dosage (113) 113
acute coronary syndrome - therapy (112) 112
antiplatelet therapy (111) 111
piperazines - pharmacology (111) 111
purinergic p2y receptor antagonists - administration & dosage (110) 110
thiophenes - pharmacology (110) 110
cardiovascular (108) 108
cardiac patients (106) 106
aspirin - therapeutic use (103) 103
prospective studies (99) 99
adenosine - adverse effects (97) 97
inhibition (96) 96
hematology (95) 95
stents (95) 95
adult (94) 94
drug therapy (93) 93
platelet function tests (93) 93
myocardial-infarction (92) 92
blood platelets (91) 91
care and treatment (91) 91
intervention (91) 91
peripheral vascular disease (87) 87
platelet aggregation inhibitors - pharmacokinetics (86) 86
percutaneous coronary intervention - adverse effects (85) 85
aggregation (84) 84
heart attacks (83) 83
myocardial infarction - drug therapy (82) 82
platelet inhibition (82) 82
trial (79) 79
adenosine - administration & dosage (77) 77
thrombosis (77) 77
piperazines - pharmacokinetics (76) 76
outcomes (74) 74
thiophenes - pharmacokinetics (74) 74
elevation myocardial-infarction (73) 73
ticlopidine - pharmacology (73) 73
transluminal angioplasty (72) 72
platelet reactivity (70) 70
artery-disease (69) 69
cardiology (69) 69
dose-response relationship, drug (69) 69
medicine, general & internal (69) 69
double-blind (66) 66
stent thrombosis (66) 66
blood platelets - metabolism (65) 65
randomized controlled trials as topic (65) 65
risk assessment (65) 65
drug administration schedule (61) 61
drug interactions (61) 61
double-blind method (60) 60
mortality (60) 60
thrombosis - prevention & control (60) 60
acute myocardial-infarction (59) 59
aspirin - administration & dosage (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (734) 734
German (18) 18
Italian (4) 4
French (3) 3
Spanish (3) 3
Turkish (2) 2
Czech (1) 1
Danish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Heart Journal, ISSN 0195-668X, 2017, Volume 38, Issue 41, pp. 3070 - 3078
Journal Article
by Sibbing, Dirk and Aradi, Dániel and Aradi, Daniel and Jacobshagen, Claudius and Gross, Lisa and Trenk, Dietmar and Geisler, Tobias and Orban, Matthias and Orban, Martin and Hadamitzky, Martin and Merkely, Béla and Kiss, Róbert Gábor and Komócsi, András and Dézsi, Csaba A and Dézsi, Csaba András and Dézsi, András Döme and Holdt, Lesca and Felix, Stephan and Felix, Stephan B and Parma, Zofia and Parma, Radoslaw and Klopotowski, Mariusz and Schwinger, Robert and Schwinger, Robert H G and Rieber, Johannes and Huber, Kurt and Neumann, Franz-Josef and Koltowski, Lukasz and Mehilli, Julinda and Huczek, Zenon and Massberg, Steffen and Lesiak, Maciej and Komosa, Anna and Kowara, Michal and Rymuza, Bartosz and Malek, Lukasz and Veress, Gábor and Lux, Árpád and Papp, Judit and Kovács, Andrea and Amer, Sayour and Ruzsa, Zoltán and Róna, Szilárd and Ili, Renáta and Ungi, Imre and Nagy, Ferenc and Zweiker, Robert and Tóth-Gayor, Gábor and Haller, Paul and von Scheidt, Wolfgang and Blüthgen, Andreas and Leggewie, Stefan and Kreider-Stempfle, Hans Ulrich and Remp, Thomas and Kara, Kaffer and Mügge, Andreas and Wutzler, Alexander and Fichtlscherer, Stephan and Zeiher, Andreas M and Seeger, Florian and Hinterseer, Martin and König, Andreas and Lederle, Susanne and Czepluch, Frauke and Maier, Lars and Schillinger, Wolfgang and Sossalla, Samuel and Hummel, Astrid and Karakas, Mahir and Sydow, Karsten and Rudolph, Tanja and Halbach, Marcel and Gori, Tommaso and Münzel, Thomas and May, Andreas and Gerstenberg, Carsten-Manuel and Pilecky, David and Deichstetter, Markus and Kääb, Stefan and Löw, Anja and Sattler, Stefan and Deuschl, Sabine and Teupser, Daniel and Mudra, Harald and Räder, Thomas and Schütz, Torsten and Vahldiek, Felix and Divchev, Dimitar and Ince, Hüseyin and Nienaber, Christoph A and Radunski, Henning and Boekstegers, Peter and Horstkotte, Jan and Mueller, Ralf and Müller, Karin and Rasp, Oliver and TROPICAL-ACS Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10104, pp. 1747 - 1757
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | THERAPY | TICAGRELOR | TREATMENT PATTERNS | PRASUGREL | DIPHOSPHATE RECEPTOR INHIBITOR | OUTCOMES | MYOCARDIAL-INFARCTION PATIENTS | PLATELET REACTIVITY | Myocardial Infarction - epidemiology | Acute Coronary Syndrome - epidemiology | Drug Administration Schedule | Hemorrhage - epidemiology | Humans | Middle Aged | Europe - epidemiology | Male | Prasugrel Hydrochloride - adverse effects | Ticlopidine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Clopidogrel | Female | Stroke - epidemiology | Hemorrhage - chemically induced | Prasugrel Hydrochloride - administration & dosage | Drug Monitoring | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors - adverse effects | Transluminal angioplasty | Care and treatment | Coronary heart disease | Cardiac patients | Analysis | Anticoagulants | Heart attacks | Blood platelets | Angioplasty | Clinical trials | Acute coronary syndromes | Drug therapy | Patients | Clinical outcomes | Myocardial infarction | Intervention | Medical services | Bleeding | Consortia | Randomization | Motivation | Inhibition | Cerebral infarction | Stroke | Test procedures | Health risks | Thrombosis | Coronary vessels | Biomarkers | Infarction | Cardiovascular diseases | Platelets
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2016, Volume 374, Issue 7, pp. 625 - 635
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 06/2019, Volume 321, Issue 24, pp. 2414 - 2427
Journal Article
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 08/2017, Volume 10, Issue 16, pp. 1646 - 1658
Objectives This study compared adenosine-associated pleiotropic effects of the 2 P2Y receptor antagonists on vascular function, systemic inflammation, and... 
pleiotropic effect | prasugrel | diabetic patients | ticagrelor | acute coronary syndrome | ADENOSINE-FREE ASSESSMENT | CARDIAC & CARDIOVASCULAR SYSTEMS | HORMONE-THERAPY | COMBINED INTRACORONARY PRESSURE | ANTIPLATELET THERAPY | DIAGNOSTIC-ACCURACY | ACUTE MYOCARDIAL-INFARCTION | CARDIOVASCULAR-DISEASE | FLOW VELOCITY INFORMATION | POSTMENOPAUSAL WOMEN | LESION SEVERITY | Prospective Studies | Non-ST Elevated Myocardial Infarction - physiopathology | Percutaneous Coronary Intervention - mortality | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Acute Coronary Syndrome - physiopathology | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Percutaneous Coronary Intervention - instrumentation | Anti-Inflammatory Agents - adverse effects | Time Factors | Seoul | Adenosine - adverse effects | Adenosine - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Non-ST Elevated Myocardial Infarction - therapy | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Endothelial Progenitor Cells - metabolism | Platelet Aggregation Inhibitors - adverse effects | Non-ST Elevated Myocardial Infarction - blood | Endothelial Progenitor Cells - drug effects | Inflammation Mediators - blood | Treatment Outcome | Prasugrel Hydrochloride - adverse effects | Biomarkers - blood | Acute Coronary Syndrome - blood | Prasugrel Hydrochloride - therapeutic use | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Adenosine - analogs & derivatives | Diabetes Mellitus, Type 2 - mortality | Acute Coronary Syndrome - therapy | Aged | Vasodilation - drug effects | Non-ST Elevated Myocardial Infarction - mortality | Percutaneous Coronary Intervention - adverse effects
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 495 - 504
The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we... 
GEMFIBROZIL | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | MARKEDLY INCREASES | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | LEUKOTRIENE-RECEPTOR ANTAGONIST | CYP2C8 SUBSTRATE PIOGLITAZONE | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Inactivation, Metabolic | Quinolines - blood | Acetates - adverse effects | Acetates - blood | Humans | Leukotriene Antagonists - pharmacokinetics | Substrate Specificity | Male | Clopidogrel - administration & dosage | Healthy Volunteers | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Drug Interactions | Leukotriene Antagonists - administration & dosage | Computer Simulation | Platelet Aggregation Inhibitors - administration & dosage | Pharmacogenomic Variants | Adult | Female | Cytochrome P-450 CYP2C8 - metabolism | Prasugrel Hydrochloride - administration & dosage | Leukotriene Antagonists - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Pharmacogenetics | Oxidation-Reduction | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Prasugrel Hydrochloride - adverse effects | Cross-Over Studies | Acetates - administration & dosage | Models, Biological | Leukotriene Antagonists - blood | Clopidogrel - adverse effects | Cytochrome P-450 CYP2C8 - genetics | Quinolines - adverse effects | Acetates - pharmacokinetics | Research | Basic Medicine | Farmakologi och toxikologi | Medical and Health Sciences | Pharmacology and Toxicology | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 12/2015, Volume 8, Issue 14, pp. 1880 - 1889
Journal Article
Clinical Research in Cardiology, ISSN 1861-0684, 4/2016, Volume 105, Issue 4, pp. 349 - 355
Morphine decreases the concentrations and effects of clopidogrel, which could lead to treatment failure in myocardial infarction.To clarify whether more potent... 
Prasugrel | Medicine & Public Health | Drug interactions | Morphine | Platelet function tests | Cardiology | Vasodilator-stimulated phosphoprotein | MORTALITY | PATHWAYS | CARDIAC & CARDIOVASCULAR SYSTEMS | PHOSPHORYLATION | REPERFUSION | ACUTE CORONARY SYNDROMES | CLOPIDOGREL | PLATELET INHIBITION | ACUTE MYOCARDIAL-INFARCTION | INTERVENTION | ACTIVE METABOLITE | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Male | Purinergic P2Y Receptor Antagonists - blood | Drug Monitoring - methods | Healthy Volunteers | Platelet Aggregation Inhibitors - blood | Young Adult | Purinergic P2Y Receptor Antagonists - adverse effects | Tandem Mass Spectrometry | Austria | Analgesics, Opioid - adverse effects | Drug Interactions | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Chromatography, Liquid | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Prasugrel Hydrochloride - administration & dosage | Prasugrel Hydrochloride - pharmacokinetics | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Risk Assessment | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Prasugrel Hydrochloride - adverse effects | Cross-Over Studies | Analgesics, Opioid - administration & dosage | Morphine - administration & dosage | Morphine - adverse effects | Prasugrel Hydrochloride - blood | Medical colleges | Metabolites | Vasodilators | Clinical trials | Liquid chromatography | Mass spectrometry | Original Paper
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 6, pp. 1104 - 1112
Summary The role of anticoagulants and antiplatelet agents in tumour growth and prognosis is not new, and currently under intense investigation. Some... 
Current controversies | Prasugrel | Aspirin | Vorapaxar | Clinical trials | Clopidogrel | Duration of antiplatelet therapy | Triple antiplatelet therapy | Ticagrelor | Cancer | clopidogrel | vorapaxar | duration of antiplatelet therapy | RANDOMIZED-TRIAL | RISK | ticagrelor | ACUTE CORONARY SYNDROMES | ATHEROTHROMBOTIC EVENTS | BREAST-CANCER | INHIBITION | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | triple antiplatelet therapy | aspirin | PERIPHERAL VASCULAR DISEASE | cancer | clinical trials | HEMATOLOGY | Species Specificity | Colonic Neoplasms - prevention & control | Humans | Male | Neoplasms, Experimental - chemically induced | Blood Platelets - physiology | Rivaroxaban - administration & dosage | Neoplasm Metastasis | Pyridines - adverse effects | Multicenter Studies as Topic | Neoplasms - chemically induced | Rivaroxaban - adverse effects | Time Factors | Lactones - administration & dosage | Adenosine - adverse effects | Ticlopidine - adverse effects | Platelet Aggregation Inhibitors - pharmacology | Ticlopidine - administration & dosage | Female | Aspirin - therapeutic use | Aspirin - pharmacology | Prasugrel Hydrochloride - administration & dosage | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Anticarcinogenic Agents - pharmacology | Anticarcinogenic Agents - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - administration & dosage | Prasugrel Hydrochloride - adverse effects | Lactones - adverse effects | Adenosine - administration & dosage | Carcinogenicity Tests | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Animals | Adenosine - analogs & derivatives | Neoplastic Cells, Circulating | Sex Factors | Mice | Neoplasms - epidemiology
Journal Article
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, ISSN 1522-1946, 10/2016, Volume 88, Issue 4, pp. 535 - 544
Journal Article